This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Spyros Papapetropoulos

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	3yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Spyros Papapetropoulos (50 yo)

less than a year

在職期間

Dr. Spyridon Papapetropoulos, M. D., Ph. D., also known as Spyros, serves as Director, President & Chief Executive Officer at Bionomics Limited from January 05, 2023. He serves as Member of Scientific Advi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Adrian Hinton	Financial Controller	less than a year	AU$323.78k	0.0048% A$ 700.6
Spyridon Papapetropoulos	CEO, President & Director	less than a year	データなし	データなし
Timothy Cunningham	Chief Financial Officer	less than a year	データなし	データなし
Paul Rolan	Consultant Chief Medical Officer of Clinical Neuroscience	no data	AU$102.00k	データなし
Julie Kerner	Senior Vice President of Business Operations	less than a year	データなし	データなし
Atul Mahableshwarkar	Acting Chief Medical Officer	less than a year	データなし	データなし
Suzanne Irwin	Company Secretary	2.3yrs	データなし	データなし

0.3yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: BNOの経営陣は経験豊富とはみなされません ( 0.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Spyridon Papapetropoulos	CEO, President & Director	less than a year	データなし	データなし
Errol B. De Souza	Non-Executive Director	15.5yrs	AU$4.03m	0.025% A$ 3.7k
David Wilson	Independent Non-Executive Director	7.2yrs	AU$87.00k	0.017% A$ 2.5k
Alan Fisher	Independent Non-Executive Chair of the Board	6.9yrs	AU$87.00k	0.0068% A$ 1.0k
Jane Ryan	Independent Non-Executive Director	2.8yrs	AU$93.15k	0% A$ 0
Srinivas Rao	Member of Clinical Advisory Board	1.8yrs	AU$57.75k	データなし
Murray Stein	Member of Clinical Advisory Board	no data	データなし	データなし
Steven Williams	Scientific Advisor	no data	データなし	データなし
Allan Young	Scientific Advisor	no data	データなし	データなし
Marina Picciotto	Scientific Advisor	no data	データなし	データなし
Peter Miles Davies	Independent Non-Executive Director	2.1yrs	AU$77.00k	0.018% A$ 2.7k
Aaron N. Weaver	Independent Non-Executive Nominee Director	3.1yrs	AU$77.00k	データなし

3.0yrs

平均在職期間

56.5yo

平均年齢

経験豊富なボード: BNOの取締役会は経験豊富ではない ( 3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

This company listing is no longer active

Bionomics マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

High number of new directors

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.011 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

Revenue beats expectations

New 90-day high: AU$0.39

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

New 90-day high: AU$0.22

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - AU$0.0082 loss per share

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04